Evaluation of cannabimimetic discriminative stimulus effects of anandamide and methylated fluoroanandamide in rhesus monkeys.
J L Wiley, K M Golden, W J Ryan, R L Balster, R K Razdan, B R Martin
Pharmacology, Biochemistry, and Behavior December 1997 DOI: 10.1016/s0091-3057(97)00327-4 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Animal drug discrimination study Peer reviewed |
|---|---|
| Population | Rhesus monkeys trained to discriminate delta9-THC from vehicle |
| Interventions | Anandamide 2-methylarachidonyl-2'-fluoroethylamide (methylated fluoroanandamide) |
| Dose | 10 mg/kg |
| Key points | Anandamide failed to reliably substitute for delta9-THC in rhesus monkeys and did not reduce response rates at doses up to 10 mg/kg, whereas the putative stable analog methylated fluoroanandamide produced full dose-dependent substitution for delta9-THC without significant response-rate changes. The authors suggest anandamide may be metabolized before behaviorally active concentrations reach the brain, and that the stable analog may aid discovery of endogenous cannabinoid system functions. |
Abstract
In previous research arachidonylethanolamide (anandamide) has been shown to produce behavioral effects in mice characteristic of psychoactive cannabinoids, including antinociception, catalepsy, hypothermia, and hypomotility. However, differences have also been found between anandamide and delta9-tetrahydrocannabinol (delta9-THC), with anandamide having lower potency, a more rapid onset, and shorter duration of action than delta9-THC. Although it can produce delta9-THC like discriminative stimulus effects in rats, anandamide also produces concomitant response rate decreasing effects, whereas with delta9-THC there is a better separation of these two behavioral effects. The present study was designed to examine the discriminative stimulus effects of anandamide in rhesus monkeys trained to discriminate delta9-THC from vehicle. While anandamide failed to produce reliable substitution for delta9-THC and did not reduce response rates at doses up to 10 mg/kg, 2-methylarachidonyl-2'-fluoroethylamide (methylated fluoroanandamide), a putative stable analog of anandamide, produced full dose-dependent substitution for delta9-THC at doses that caused no significant changes in response rates. These results suggest that systemically administered anandamide may be metabolized in monkeys before behaviorally active concentrations could reach the brain and further suggest that the metabolically more stable analog of anandamide, methylated fluoroanandamide, may aid in the discovery of functional properties of the endogenous cannabinoid system.
Citations in the library
Cited by 13
- Discriminative Stimulus Properties of Phytocannabinoids, Endocannabinoids, and Synthetic Cannabinoids. Current Topics in Behavioral Neurosciences 2018
- Discriminative Stimulus Properties of the Endocannabinoid Catabolic Enzyme Inhibitor SA-57 in Mice. Journal of Pharmacology and Experimental Therapeutics August 2016
- Phenotypic assessment of THC discriminative stimulus properties in fatty acid amide hydrolase knockout and wildtype mice. Neuropharmacology June 2015
- The fatty acid amide hydrolase inhibitor URB 597: interactions with anandamide in rhesus monkeys. British Journal of Pharmacology September 2011
- The endogenous cannabinoid anandamide shares discriminative stimulus effects with ∆(9)-tetrahydrocannabinol in fatty acid amide hydrolase knockout mice. European Journal of Pharmacology April 10, 2011
and 8 more in the library
Cites 3
- Discriminative stimulus effects of CP 55,940 and structurally dissimilar cannabinoids in rats. Neuropharmacology June 1995
- Pharmacological specificity of delta 9-tetrahydrocannabinol discrimination in rats. Psychopharmacology April 1995
- Discriminative stimulus effects of delta 9-tetrahydrocannabinol and delta 9-11-tetrahydrocannabinol in rats and rhesus monkeys. Neuropharmacology April 1993